Neon Therapeutics, which is developing a targeted immunotherapy platform for various cancers, filed on Thursday with the SEC to raise up to $115 million in an initial public offering.
The Cambridge, MA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol NTGN. Neon Therapeutics filed confidentially on February 12, 2017. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
